{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T09:59:18Z","timestamp":1790589558773,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"DOI":"10.1186\/s41927-026-00696-y","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:54:59Z","timestamp":1790326499000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal clinical outcomes after the escalation of subcutaneous tocilizumab from every 2 weeks to once weekly in rheumatoid arthritis with inadequate disease control: A 52-week real-world observational study"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6767-6895","authenticated-orcid":false,"given":"Masanori","family":"Sudo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayuri","family":"Takamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asami","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Nakazono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Murasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"issue":"10055","key":"696_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023\u201338.","journal-title":"Lancet"},{"issue":"7","key":"696_CR2","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924\u201339.","journal-title":"Arthritis Care Res"},{"issue":"6","key":"696_CR3","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685\u201399. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"696_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","volume":"80","author":"G Nagy","year":"2021","unstructured":"Nagy G, Roodenrijs NMT, Welsing PMJ, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021;80(1):31\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"696_CR5","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1002\/art.23940","volume":"58","author":"MC Genovese","year":"2008","unstructured":"Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58(10):2968\u201380. https:\/\/doi.org\/10.1002\/art.23940.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"696_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1136\/annrheumdis-2013-203523","volume":"73","author":"GR Burmester","year":"2014","unstructured":"Burmester GR, Rubbert-Roth A, Cantagrel A, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis. 2014;73(1):69\u201374. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203523.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"696_CR7","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1136\/ard.2010.139725","volume":"70","author":"GR Burmester","year":"2011","unstructured":"Burmester GR, Feist E, Kellner H, Braun J, Iking-Konert C, Rubbert-Roth A. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis. 2011;70(5):755\u20139. https:\/\/doi.org\/10.1136\/ard.2010.139725.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"696_CR8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/ard.2008.105197","volume":"69","author":"G Jones","year":"2010","unstructured":"Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88\u201396. https:\/\/doi.org\/10.1136\/ard.2008.105197.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"696_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0140-6736(04)16676-2","volume":"22","author":"H Yamanaka","year":"2012","unstructured":"Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364(9430):263\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(04)16676-2.","journal-title":"Mod Rheumatol"},{"issue":"6","key":"696_CR10","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1136\/annrheumdis-2015-207760","volume":"28","author":"H Hanaoka","year":"2018","unstructured":"Gabay C, Riek M, Hetland ML, et al. Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study. Ann Rheum Dis. 2016;75(7):1336\u201342. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207760.","journal-title":"Mod Rheumatol"},{"issue":"2","key":"696_CR11","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3899\/jrheum.141210","volume":"27","author":"S Ito","year":"2017","unstructured":"Yamamoto K, Goto H, Hirao K, et al. Longterm safety of tocilizumab: results from 3 years of followup postmarketing surveillance of 5573 patients with rheumatoid arthritis in Japan. J Rheumatol. 2015;42(8):1368\u201375. https:\/\/doi.org\/10.3899\/jrheum.141210.","journal-title":"Mod Rheumatol"},{"issue":"1","key":"696_CR12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/14397595.2017.1332507","volume":"28","author":"A Ogata","year":"2018","unstructured":"Ogata A, Tanaka Y, Ishii T, Kaneko M, Miwa H, Ohsawa S; SHINOBI study group. A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: results of the 12-week double-blind period. Mod Rheumatol. 2018;28(1):76\u201384. https:\/\/doi.org\/10.1080\/14397595.2017.1332507.","journal-title":"Mod Rheumatol"},{"key":"696_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/art.27740","volume":"28","author":"N Nishimoto","year":"2005","unstructured":"Smolen JS, Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum. 2011;63(1):43\u201352. https:\/\/doi.org\/10.1002\/art.27740.","journal-title":"Clin Rev Allergy Immunol"},{"key":"696_CR14","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/ckj\/sfac036","volume":"15","author":"H Hanaoka","year":"2022","unstructured":"Hanaoka H, Kikuchi J, Hiramoto K, Saito S, Kondo Y, Kaneko Y. Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs. Clin Kidney J. 2022;15(7):1373\u20138. https:\/\/doi.org\/10.1093\/ckj\/sfac036.","journal-title":"Clin Kidney J"},{"issue":"3","key":"696_CR15","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1080\/14397595.2017.1332471","volume":"30","author":"M Hara","year":"2020","unstructured":"Takeuchi T, Ishida K, Shiraki K, Yoshiyasu T. Safety and effectiveness of tacrolimus add-on therapy for rheumatoid arthritis patients without an adequate response to biological disease-modifying anti-rheumatic drugs (DMARDs): post-marketing surveillance in Japan. Mod Rheumatol. 2018;28(1):48\u201357. https:\/\/doi.org\/10.1080\/14397595.2017.1332471.","journal-title":"Mod Rheumatol"},{"issue":"2","key":"696_CR16","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1080\/14397595.2018.1460230","volume":"40","author":"Q Zhu","year":"2021","unstructured":"Mimori T, Harigai M, Atsumi T, et al. Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: final report of a 52-week, multicenter postmarketing surveillance study. Mod Rheumatol. 2019;29(2):314\u201323. https:\/\/doi.org\/10.1080\/14397595.2018.1460230.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"696_CR17","doi-asserted-by":"publisher","first-page":"667","DOI":"10.14961\/cra.31.145","volume":"30","author":"E Hasegawa","year":"2020","unstructured":"Hasegawa E, Kobayashi D, Ito S, Ishikawa H, Narita I. The influence of iguratimod on renal function. Clin Rheumatol Relat Res. 2019;31(2):145\u201354. https:\/\/doi.org\/10.14961\/cra.31.145.","journal-title":"Mod Rheumatol"},{"issue":"3","key":"696_CR18","doi-asserted-by":"publisher","first-page":"620","DOI":"10.2169\/internalmedicine.5899-25","volume":"31","author":"D Nakagomi","year":"2021","unstructured":"Hanai S, Kobayashi Y, Watanabe M, et al. Risk of kidney impairment during iguratimod therapy for rheumatoid arthritis patients: the role of concomitant salazosulfapyridine. Intern Med. 2026;65(7):987\u201396. https:\/\/doi.org\/10.2169\/internalmedicine.5899-25.","journal-title":"Mod Rheumatol"},{"key":"696_CR19","first-page":"632","volume":"52","author":"P Ejaz","year":"2004","unstructured":"Ejaz P, Bhojani K, Joshi VR. NSAIDs and kidney. J Assoc Physicians India. 2004;52:632\u201340.","journal-title":"J Assoc Physicians India"},{"issue":"9","key":"696_CR20","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569\u201381.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"696_CR21","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"696_CR22","doi-asserted-by":"publisher","first-page":"R796","DOI":"10.1186\/ar1740","volume":"7","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Nell VPK, Stamm T, Uffmann M, Pflugbeil S, Machold K, Smolen JS. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7(4):R796\u2013806. https:\/\/doi.org\/10.1186\/ar1740.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"696_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/ije\/dyh299","volume":"34","author":"AG Barnett","year":"2005","unstructured":"Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it. Int J Epidemiol. 2005;34(1):215\u201320. https:\/\/doi.org\/10.1093\/ije\/dyh299.","journal-title":"Int J Epidemiol"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-026-00696-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-026-00696-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-026-00696-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T09:40:48Z","timestamp":1790588448000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41927-026-00696-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["696"],"URL":"https:\/\/doi.org\/10.1186\/s41927-026-00696-y","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"12 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki. The study protocol was approved by the Institutional Ethics Committee of the Niigata Rheumatic Center (approval number: 2025-025). Given the retrospective nature of the study, the requirement for written informed consent was waived by the Ethics Committee. Information about the study and the opportunity to opt out were made available through the hospital website and institutional bulletin board.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MS received an honorarium from Chugai Pharmaceutical Co., Ltd. for participation in a local scientific meeting at which preliminary work related to the topic of this manuscript was presented. Chugai Pharmaceutical Co., Ltd. provided no funding or other support for this study and had no role in the study design, data collection, statistical analyses, interpretation of the results, manuscript preparation, or the decision to submit the manuscript. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"74"}}